CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...
NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...
The Federal Trade Commission (FTC) has charged the marketers of a vision improvement app, called UltimEyes, with deceptively claiming they their program was scientifically proven to improve the user's ...
Add Yahoo as a preferred source to see more of our stories on Google. USC Roski Eye Institute researchers are launching a phase 2b trial of a stem cell retinal implant designed to replace damaged ...
Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...
Hrithik Roshan recently shared that his eye power reduced by nearly half, sparking widespread curiosity. “At 42, my ever-so-proper eye doctor laughed and lovingly said to me: "Haha, no, I am sorry, ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial following a successful Phase II study of its gene therapy in Stargardt disease.
The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times better after they received gene therapy to address the genetic ...
Please provide your email address to receive an email when new articles are posted on . Access to low-vision services led to significant improvement in vision and quality of life for patients with ...
SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, ...